Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.
dc.contributor.author | Youngson, J H | |
dc.contributor.author | Jones, J M | |
dc.contributor.author | Chang, James | |
dc.contributor.author | Harris, M A | |
dc.contributor.author | Banerjee, Saumitra S | |
dc.date.accessioned | 2010-05-19T09:59:42Z | |
dc.date.available | 2010-05-19T09:59:42Z | |
dc.date.issued | 1995-09 | |
dc.identifier.citation | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. 1995, 72 (3):757-65 Br. J. Cancer | en |
dc.identifier.issn | 0007-0920 | |
dc.identifier.pmid | 7669590 | |
dc.identifier.uri | http://hdl.handle.net/10541/99261 | |
dc.description.abstract | Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients. | |
dc.language.iso | en | en |
dc.subject | Leukaemia | en |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | England | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell | |
dc.subject.mesh | Leukemia, Lymphoid | |
dc.subject.mesh | Lymphoma, Non-Hodgkin | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
dc.subject.mesh | Registries | |
dc.subject.mesh | Survival Rate | |
dc.title | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. | en |
dc.type | Article | en |
dc.contributor.department | Merseyside and Cheshire Cancer Registry, University of Liverpool, UK. | en |
dc.identifier.journal | British Journal of Cancer | en |
html.description.abstract | Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients. |